|
| PD (mm) | BoP (%) | CFFR (µl) | Calprotectin (µg/µl) | MPO (µg/µl) |
| Baseline | 8.1±0.9 | 91±29 | 0.50±0.21 | 34.5±28.8 | 1.1±1.6 |
| 3 Months | 4.1±1.4 | 26±45 | 0.29±0.14 | 17±14.1 | 0.4±0.3 |
| p | <0.001 | <0.001 | <0.001 | 0.006 | 0.002 |
(Wilcoxon signed rank test)
Calprotectin/MPO (Baseline) Calprotectin/MPO (3 Months) ΔCalprotectin/ΔMPO Correlation (Pearson) 0.714 0.540 0.716 p <0.001 0.008 0.001
GCF-Levels of calprotectin and MPO correlated strongly at baseline as well as after 3 months. All parameters were markedly improved after therapy. Changes of calprotectin and MPO levels were highly correlated.
Conclusion:
Due to a strong correlation to MPO, main proportions of calprotectin in GCF may be of PMN origin. Supported by German Research Foundation (DFG) GRK 325